Enoxaparin prevents progression of stages I and II osteonecrosis of the hip.

@article{Glueck2005EnoxaparinPP,
  title={Enoxaparin prevents progression of stages I and II osteonecrosis of the hip.},
  author={Charles J Glueck and Richard A. Freiberg and Luann Sieve and Ping Wang},
  journal={Clinical orthopaedics and related research},
  year={2005},
  volume={435},
  pages={164-70}
}
UNLABELLED In a prospective pilot study, we hypothesized that enoxaparin (60 mg/day for 12 weeks) would prevent progression of Stages I and II osteonecrosis of the hip associated with thrombophilia or hypofibrinolysis or both over > or = 108 weeks of followup versus untreated historic controls, with different treatment responses in primary versus corticosteroid-associated secondary osteonecrosis. Patients with one or more thrombophilic-hypofibrinolytic disorder and Ficat Stages I or II… CONTINUE READING